Ayyıldız Sema Nur, Ayyıldız Ali
Department of Biochemical, Ordu University Faculty of Medicine, Ordu, Turkey.
Department of Urology, Ordu University Faculty of Medicine, Ordu, Turkey.
Turk J Urol. 2014 Jun;40(2):82-8. doi: 10.5152/tud.2014.94547.
Currently, prostate- specific antigen (PSA) is the most common oncological marker used for prostate cancer screening. However, high levels of PSA in benign prostatic hyperplasia and prostatitis decrease the specificity of PSA as a cancer marker. To increase the specificity of PSA, PSA derivatives and PSA kinetics have been used. However, these new techniques were not able to increase the diagnostic specificity for prostate cancer. Therefore, the search for new molecules and derivatives of PSA continues. With the aim of increasing the specificity of prostate cancer diagnosis, proPSA and the Prostate Health Index have been introduced. In this review, the roles of PSA, PSA derivatives, proPSA and the Prostate Health Index in Prostate Cancer diagnosis are examined.
目前，前列腺特异性抗原（PSA）是用于前列腺癌筛查的最常见肿瘤标志物。然而，良性前列腺增生和前列腺炎中高水平的PSA降低了PSA作为癌症标志物的特异性。为了提高PSA的特异性，人们使用了PSA衍生物和PSA动力学。然而，这些新技术未能提高前列腺癌的诊断特异性。因此，对PSA新分子和衍生物的探索仍在继续。为了提高前列腺癌诊断的特异性，前列腺特异性抗原（proPSA）和前列腺健康指数已被引入。在本综述中，将探讨PSA、PSA衍生物、proPSA和前列腺健康指数在前列腺癌诊断中的作用。
